Ipsen: collaboration agreement with Skyhawk
This agreement gives Ipsen the option to acquire an exclusive license for the worldwide development rights to validated drug candidates. Once the development candidate has been selected, it will be responsible for all activities relating to it.
Skyhawk is eligible for an upfront payment for the research collaboration, payments conditional on option exercise and regulatory and commercial milestones, for a total of up to $1.8 billion, as well as potential royalties.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction